PULMICORT RESPULES
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PULMICORT RESPULES (PULMICORT RESPULES).
Glucocorticoid receptor agonist; anti-inflammatory; decreases cytokine production, inhibits inflammatory cell migration, and reduces airway hyperresponsiveness.
| Metabolism | Hepatic via CYP3A4; primarily metabolized to 16α-hydroxyprednisolone and 6β-hydroxybudesonide. |
| Excretion | Renal: negligible (<5% as unchanged drug). Biliary/fecal: major route, approximately 60-70% as metabolites. Total clearance: 0.5-1.0 L/h. |
| Half-life | Terminal half-life approximately 2-3 hours in children and adults; slightly prolonged in hepatic impairment. Clinical context: supports twice-daily dosing in asthma. |
| Protein binding | Approximately 85-90% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Vd approximately 3-4 L/kg. Indicates extensive tissue distribution and high lipophilicity. |
| Bioavailability | Inhalation via nebulizer: approximately 10-15% of delivered dose reaches systemic circulation; oral bioavailability <1% due to first-pass metabolism. |
| Onset of Action | Inhalation via nebulizer: clinical improvement within 2-8 days; maximum effect may take 2-4 weeks. |
| Duration of Action | Duration up to 12 hours after nebulization; sustained effect with regular dosing. Clinical note: not for acute bronchospasm. |
0.5 mg to 1 mg twice daily via nebulization; for maintenance or as replacement therapy, initiate at 0.25 mg twice daily and titrate to clinical response.
| Dosage form | SUSPENSION |
| Renal impairment | No dosage adjustment required for renal impairment; drug undergoes extensive hepatic metabolism with minimal renal excretion. |
| Liver impairment | No specific guidelines for Child-Pugh; caution advised in severe hepatic impairment due to potential reduced clearance, but no routine dose adjustment recommended. |
| Pediatric use | Children 12 months to 8 years: 0.25 mg to 0.5 mg twice daily, or 0.5 mg once daily; for moderate-to-severe asthma, up to 1 mg twice daily; infants under 12 months: 0.25 mg twice daily or 1 mg once daily (limited data). Use nebulizer with appropriate mask or mouthpiece. |
| Geriatric use | No specific dose adjustment; use lowest effective dose due to potential for increased systemic effects; monitor for adrenal suppression and bone density loss with long-term use. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PULMICORT RESPULES (PULMICORT RESPULES).
| Breastfeeding | Budesonide is excreted into breast milk in low levels; M/P ratio approximately 0.25; estimated infant daily dose <1% of maternal weight-adjusted dose; consider infant exposure risk versus benefits of maternal therapy. |
| Teratogenic Risk | Inhaled corticosteroids like budesonide are not associated with increased risk of congenital malformations in first trimester; second and third trimester use may increase risk of preterm birth and low birth weight but benefits of asthma control outweigh risks. |
■ FDA Black Box Warning
No FDA boxed warning.
| Serious Effects |
["Hypersensitivity to budesonide or any component","Status asthmaticus (primary treatment)"]
| Precautions | ["Risk of adrenal insufficiency with systemic absorption","Increased susceptibility to infections","Oropharyngeal candidiasis","Growth suppression in pediatric patients","Ocular effects (glaucoma, cataracts)"] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal asthma symptoms, peak expiratory flow, and fetal growth via ultrasound; assess for intrauterine growth restriction; monitor for signs of adrenal suppression in mother or infant with prolonged high-dose use. |
| Fertility Effects | No significant adverse effects on fertility in animal studies; in humans, uncontrolled asthma may impair fertility, but budesonide use is not linked to reduced fertility. |